Reference priceJPY ¥91,875.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Tevimbra |
|---|---|
| Manufacturer | BeOne Medicines GmbH |
| Prescription required | Yes |
Tevimbra 100mgInfusionsl sungs,1pce x 10ml(Tislelizumab)
Tislelizumab
Description
Tevimbra 100mgInfusionsl sungs,1pce x 10ml(Tislelizumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: Tislelizumab. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: BeOne Medicines GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Esophageal carcinoma (squamous cell carcinoma of the esophagus. Pack information: 100 / 10, 10. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer Gastric Cancer Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy in adults for the first line treatment of HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.How to Use
Use Tislelizumab under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Tislelizumab. Pack size: 100 / 10, 10. Pack unit: bottle. Manufacturer: BeOne Medicines GmbH. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Esophageal carcinoma (squamous cell carcinoma of the esophagus. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。